Browse result page of AntiTbPdb
The total number entries retrieved from this search are 124
| ID | Name | Sequence | N-Terminal Modification | C-Terminal Modification | Chemical Modification | Linear/Cyclic | Length | Chirality | Nature | Source | Origin | Species | Strain | Inhibition Concentration | In vitro/ In vivo | Cell Line | Intracellular Inhibition | Cytotoxicity | Animal Model | Effective Dose in model organism | Immune Responce | Mechanism of Action | Target | Combination Therapy | Other Activities | Year of Publication | Pubmed ID/ Patent No. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| antitb_1177 | D-LFcin17-30 | fkcrrwqwrmkklg | Free | Free | None | Linear | 14 | D | Cationic | Synthetic | NA | Mycobacterium avium | Mycobacterium avium strain 2447 smooth transparent variant (SmT) | IC50 = 10.7 ± 0.9 | In vitro | None | NA | NA | None | NA | NA | Permeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells. | Cell envelope | None | None | 2014 | 24709266 |
| antitb_1178 | D-LFcin17-30 | fkcrrwqwrmkklg | Free | Free | None | Linear | 14 | D | Cationic | Synthetic | NA | Mycobacterium avium | Mycobacterium avium strain 2447 smooth transparent variant (SmT) | IC90 = 14.4 ± 1.9 | In vitro | None | NA | NA | None | NA | NA | Permeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells. | Cell envelope | None | None | 2014 | 24709266 |
| antitb_1317 | D-LL37 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRN | Free | Free | None | Linear | 31 | D | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 200 μg/mL | In vitro | Human erythrocyte | NA | HC50 = 125 μg/mL | NA | NA | NA | NA | NA | NA | NA | 2011 | 20858205 |
| antitb_1478 | Lariatin A | GSQLVYRWVGHSNVIKGP | NA | NA | Alpha carbon of glutamine form amide bond with first glycine and gamma carbon of glutamine involved in side chain formation | Cyclic | 18 | D | Cationic | Natural | Derived from Rhodococcusjostii K01â€B0171 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | MIC = 0.39 mg/L | in vitro | NA | NA | NA | NA | NA | NA | Inhibit cell wall biosynthesis | NA | NA | NA | 2015 | 25681127 |
| antitb_1479 | Dihydromycoplanecin A (DHMP A) | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Actinoplanesawajinensis | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | IC50= 0.0125-25mg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 |
| antitb_1480 | Dihydromycoplanecin A (DHMP A) | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Actinoplanesawajinensis | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | IC90= 0.05 μg/mL | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 |
| antitb_1481 | Dihydromycoplanecin A (DHMP A) | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Actinoplanesawajinensis | Mycobacterium intracellulare | Mycobacterium intracellulare | IC50= 1.56 μg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 |
| antitb_1482 | Dihydromycoplanecin A (DHMP A) | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Actinoplanesawajinensis | Mycobacterium intracellulare | Mycobacterium intracellulare | IC90= 25 μg/mL | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 |
| antitb_1483 | Dihydromycoplanecin A (DHMP A) | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Actinoplanesawajinensis | Mycobacteria kansaii | Mycobacteria kansaii | IC50= 0.39 μg/mL | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 |
| antitb_1484 | Dihydromycoplanecin A (DHMP A) | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Actinoplanesawajinensis | Mycobacteria kansaii | Mycobacteria kansaii | IC90= 0.78 μg/mL | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 |
| antitb_1485 | Dihydromycoplanecin A (DHMP A) | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Actinoplanesawajinensis | Mycobacteria smegmatis | Mycobacteria smegmatis ATCC 607 | MIC = 12.5 μg/mL | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | DHMP A + INH | NA | 2015 | 25681127 |
| antitb_1486 | Pitipeptolides A | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Cyanobacterium Lyngbya majuscula | Mycobacterium tuberculosis | Mycobacteria smegmatis ATCC 25177 | Reduction in zone of growth to 25 mm at 100 μg conc. | LoVo cancer cells | NA | IC50= 2.25 μg/ml for M.Smegmatis ATCC 25177 | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 | |
| antitb_1487 | Pitipeptolides A | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Cyanobacterium Lyngbya majuscula | Mycobacterium tuberculosis | Mycobacteria smegmatis ATCC 25177 | Reduction in zone of growth to 10 mm at 25 μg | LoVo cancer cells | NA | IC50= 2.25μg/ml for M.Smegmatis ATCC 25177 | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 | |
| antitb_1488 | Pitipeptolides A | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Cyanobacterium Lyngbya majuscula | Mycobacterium tuberculosis | Mycobacteria smegmatis ATCC 35818 | Reduction in zone of growth to 15 mm at 100 μg | LoVo cancer cells | NA | IC50= 1.95 μg/ml for m.Smegmatis ATCC35818 | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 | |
| antitb_1489 | Pitipeptolides A | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Cyanobacterium Lyngbya majuscula | Mycobacterium tuberculosis | Mycobacteria smegmatis ATCC 35818 | Reduction in zone of growth to 9 mm at 25 μg | LoVo cancer cells | NA | IC50= 1.95 μg/ml for m.Smegmatis ATCC35818 | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 | |
| antitb_1490 | Pitipeptolides A | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Cyanobacterium Lyngbya majuscula | Mycobacterium tuberculosis | Mycobacteria smegmatis ATCC 25177 | Reduction in zone of growth to 30 mm at 100 μg | LoVo cancer cells | NA | IC50= 2.25 μg/ml for M.Smegmatis ATCC 25177 | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 | |
| antitb_1491 | Pitipeptolides A | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Cyanobacterium Lyngbya majuscula | Mycobacterium tuberculosis | Mycobacteria smegmatis ATCC 25177 | Reduction in zone of growth to 15 mm at 25 μg | LoVo cancer cells | NA | IC50= 2.25μg/ml for M.Smegmatis ATCC 25177 | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 | |
| antitb_1492 | Pitipeptolides A | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Cyanobacterium Lyngbya majuscula | Mycobacterium tuberculosis | Mycobacteria smegmatis ATCC 35818 | Reduction in zone of growth to 15 mm at 100 μg | LoVo cancer cells | NA | IC50= 1.95 μg/ml for m.Smegmatis ATCC35818 | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 | |
| antitb_1493 | Pitipeptolides A | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Cyanobacterium Lyngbya majuscula | Mycobacterium tuberculosis | Mycobacteria smegmatis ATCC 35818 | Reduction in zone of growth to 10 mm at 25 μg | LoVo cancer cells | NA | IC50= 1.95 μg/ml for m.Smegmatis ATCC35818 | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 | |
| antitb_1494 | Lacticin 3147 | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Lactococcuslactis | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37 Ra | IC90= 7.5 mg/ml (±0.36) | in vitro | NA | NA | NA | NA | NA | NA | Inhibit biosynthesis of peptidoglycan and form pores in bacterial membrane | NA | NA | NA | 2015 | 25681127 |
| antitb_1495 | Lacticin 3148 | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Lactococcuslactis | Mycobacterium tuberculosis | Mycobacteria kansasii CIT11/06 | IC90= 60 mg/ml (±0.75) | in vitro | NA | NA | NA | NA | NA | NA | Inhibit biosynthesis of peptidoglycan and form pores in bacterial membrane | NA | NA | NA | 2015 | 25681127 |
| antitb_1496 | Lacticin 3149 | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Lactococcuslactis | Mycobacterium avium | Mycobacterium avium subspecies paratuberculosis ATCC 19698 | IC90= 15mg/ml (±0.30) | in vitro | NA | NA | NA | NA | NA | NA | Inhibit biosynthesis of peptidoglycan and form pores in bacterial membrane | NA | NA | NA | 2015 | 25681127 |
| antitb_1497 | Nisin A | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Lactococcus lactis | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37 Ra | IC90= >60mg/ml (±0.18) | in vitro | NA | NA | NA | NA | NA | NA | Inhibit biosynthesis of peptidoglycan and form pores in bacterial membrane | NA | NA | NA | 2015 | 25681127 |
| antitb_1498 | Nisin A | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Lactococcuslactis | Mycobacterium tuberculosis | Mycobacteria kansasii CIT11/06 | IC90= 60 mg/ml (±0.13) | in vitro | NA | NA | NA | NA | NA | NA | Inhibit biosynthesis of peptidoglycan and form pores in bacterial membrane | NA | NA | NA | 2015 | 25681127 |
| antitb_1499 | Nisin A | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Lactococcuslactis | Mycobacterium avium | Mycobacterium avium subspecies paratuberculosis ATCC 19698 | IC90= >60 mg/ml (± 2.02) | in vitro | NA | NA | NA | NA | NA | NA | Inhibit biosynthesis of peptidoglycan and form pores in bacterial membrane | NA | NA | NA | 2015 | 25681127 |
| antitb_1500 | Sansanmycins A (Ssa) | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Streptomyces species | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | IC50= 16 μg/ml | in vitro | NA | NA | NA | NA | NA | NA | Inhibit the MraY translocase present in the bacterial cell membrane | NA | NA | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas | 2015 | 25681127 |
| antitb_1501 | Sansanmycins A (Ssa) | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Streptomyces species | Mycobacterium tuberculosis | Mycobacterium tuberculosis 2199 | IC50= 32 μg/ml | In vitro | NA | NA | NA | NA | NA | NA | Inhibit the MraY translocase present in the bacterial cell membrane | NA | NA | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas | 2015 | 25681127 |
| antitb_1502 | Cyclomarin A | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Streptomyces species | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | IC50= 0.3mg/ml | in vitro | NA | NA | NA | NA | NA | Change the clp1subunit of casinolytic protease by allosteric binding | NA | NA | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas | 2015 | 25681127 | |
| antitb_1503 | Massetolide A | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Pseudomonas fluorescens SS101 | Mycobacterium tuberculosis | Mycobacterium tuberculosis h37RV | MIC = 5 mg/ml | in vitro | NA | NA | NA | NA | NA | interfere with bacterial cell wall biosynthesis | NA | NA | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas | 2015 | 25681127 | |
| antitb_1504 | Visconsin | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Pseudomonas species | Mycobacterium tuberculosis | Mycobacterium avium intercellularae | MIC = 10 mg/ml | in vitro | NA | NA | NA | NA | NA | interfere with bacterial cell wall biosynthesis | NA | NA | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas | 2015 | 25681127 | |
| antitb_1505 | Bacitracin | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Bacillus subtilis | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 130mg/ml | in vitro | NA | NA | NA | NA | NA | NA | inhibit bacterial cell wall synthesis | NA | NA | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas | 2015 | 25681127 |
| antitb_1507 | SP508B | R-(zDhb)-PVLALVAAVAATSAAY | R =3-hydroxyldodecanoyl | Free | Dhb= Dihydrobutyric acid, o-C=o linkage between 12 and 16 amino acid residue | Cyclic | 18 | D | Cationic | Natural | Derived from Pseudomonas syringae | Mycobacterium smegmatis | Mycobacterium smegmatis ATCC14468 | MIC = 62.5 μg/ml | in vitro | NA | NA | NA | NA | NA | Specific interaction with membrane | NA | NA | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas | 2015 | 25681127 | |
| antitb_1509 | SP22B | R-(zDhb)-PVVAAVVAVAASAAY | R =3-hydroxyldodecanoyl | Free | Dhb= Dihydrobutyric acid, o-C=o linkage between 12 and 16 amino acid residue | cyclic | 18 | D | Cationic | Natural | Derived from Pseudomonas syringae | Mycobacterium smegmatis | Mycobacterium smegmatis ATCC14468 | MIC = 31.25 μg/ml | in vitro | NA | NA | NA | NA | NA | Specific interaction with membrane | NA | NA | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas | 2015 | 25681127 | |
| antitb_1511 | SP508B | R-(zDhb)-PVLALVAAVAATSAAY | R =3-hydroxyldodecanoyl | Free | Dhb= Dihydrobutyric acid, o-C=o linkage between 12 and 16 amino acid residue | Cyclic | 18 | D | Cationic | Natural | Derived from Pseudomonas syringae | Mycobacterium smegmatis | Mycobacterium smegmatis ATCC14468 | Reduction in zone to 18 mm at 62.5 mg/L | in vitro | NA | NA | NA | NA | NA | Specific interaction with membrane | NA | NA | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas | 2015 | 25681127 | |
| antitb_1513 | SP22B | R-(zDhb)-PVVAAVVAVAASAAY | R =3-hydroxyldodecanoyl | Free | Dhb= Dihydrobutyric acid, o-C=o linkage between 12 and 16 amino acid residue | cyclic | 18 | D | Cationic | Natural | Derived from Pseudomonas syringae | Mycobacterium smegmatis | Mycobacterium smegmatis ATCC14468 | Reduction in zone to 14 mm at 31.25 mg/L | in vitro | NA | NA | NA | NA | NA | Specific interaction with membrane | NA | NA | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas | 2015 | 25681127 | |
| antitb_1514 | Hirsutatins A | not available | Free | Free | None | Branched cyclic | 0 | D | Cationic | Natural | Derived from Hirsutellanivea | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC =50 mg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 |
| antitb_1515 | Hirsutatins B | not available | Free | Free | None | Branched cyclic | 0 | D | Cationic | Natural | Derived from Hirsutellanivea | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 50 mg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 |
| antitb_1546 | Lassomycin | GLRRLFADQLVGRRN | Free | Methylation | Free NH- group of first Glycine form NHCO bond with CO group of eight Asparagine to form cyclic bond | Cyclic | 15 | D | Cationic | Natural | Derived from lentzea kentuckyensis | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | IC50 = 0.8-3 mg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 25613372 |
| antitb_1547 | Lassomycin | GLRRLFADQLVGRRN | Free | Methylation | Free NH- group of first Glycine form NHCO bond with CO group of eight Asparagine to form cyclic bond | Cyclic | 15 | D | Cationic | Natural | Derived from lentzea kentuckyensis | Mycobacterium tuberculosis | Mycobacterium tuberculosis MDR | IC50= 0.8-3 mg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 25613372 |
| antitb_1548 | Lassomycin | GLRRLFADQLVGRRN | Free | Methylation | Free NH- group of first Glycine form NHCO bond with CO group of eight Asparagine to form cyclic bond | Cyclic | 15 | D | Cationic | Natural | Derived from lentzea kentuckyensis | Mycobacterium tuberculosis | Mycobacterium tuberculosis XDR | IC50= 0.8-3 mg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 25613372 |
| antitb_1630 | Callyaerins 6 | I-(Hyp)-VILPPLPIFG | Free | Amidation | Hyp= Hydroxiproline, Residue 1-8 involved in cyclic bond formation | Cyclic | 12 | D | Cationic | Natural | Derived from Callyspongia aerizusa | Mycobacterium Tuberculosis | Mycobacterium tuberculosis H37Rv | IC90= 2 μg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 26213786 |
| antitb_1631 | Callyaerins 6 | I-(Hyp)-VILPPLPIFG | Free | Amidation | Hyp= Hydroxiproline, Residue 1-8 involved in cyclic bond formation | Cyclic | 12 | D | Cationic | Natural | Derived from Callyspongia aerizusa | Mycobacterium Tuberculosis | Mycobacterium tuberculosis H37Rv | MIC= 6 μg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 26213786 |
| antitb_1632 | Callyaerins 6 | I-(Hyp)-VILPPLPIFG | Free | Amidation | Hyp= Hydroxiproline, Residue 1-8 involved in cyclic bond formation | Cyclic | 12 | D | Cationic | Natural | Derived from Callyspongia aerizusa | NA | in vitro on THP1 cell line | IC50= 30 μg/ml | in vitro | THP-1 cell line | 50% reduction in bacterial load | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 26213786 |
| antitb_1633 | Callyaerins 6 | I-(Hyp)-VILPPLPIFG | Free | Amidation | Hyp= Hydroxiproline, Residue 1-8 involved in cyclic bond formation | Cyclic | 12 | D | Cationic | Natural | Derived from Callyspongia aerizusa | NA | in vitro on THP1 cell line | IC90= 50 μg/ml | in vitro | THP-1 cell line | 90% reduction in bacterial load | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 26213786 |
| antitb_1634 | Callyaerins 6 | I-(Hyp)-VILPPLPIFG | Free | Amidation | Hyp= Hydroxiproline, Residue 1-8 involved in cyclic bond formation | Cyclic | 12 | D | Cationic | Natural | Derived from Callyspongia aerizusa | NA | in vitro on MRC-5 cell lines | IC50= 20 μg/ml | in vitro | MRC-5 cell lines | 50% reduction in bacterial load | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 26213786 |
| antitb_1635 | Callyaerins 6 | I-(Hyp)-VILPPLPIFG | Free | Amidation | Hyp= Hydroxiproline, Residue 1-8 involved in cyclic bond formation | Cyclic | 12 | D | Cationic | Natural | Derived from Callyspongia aerizusa | NA | in vitro on MRC-5 cell lines | IC90 = 40 μg/ml | in vitro | MRC-5 cell lines | 90% reduction in bacterial load | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 26213786 |
| antitb_1636 | Callyaerins 7 | I-(Hyp)-VILPPLPIFG | Free | Amidation | Hyp= Hydroxiproline, Residue 1-8 involved in cyclic bond formation | Cyclic | 11 | D | Cationic | Natural | Derived from Callyspongia aerizusa | Mycobacterium Tuberculosis | Mycobacterium tuberculosis H37Rv | IC90 =5 μg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 26213786 |
| antitb_1637 | Callyaerins 7 | I-(Hyp)-VILPPLPIFG | Free | Amidation | Hyp= Hydroxiproline, Residue 1-8 involved in cyclic bond formation | Cyclic | 11 | D | Cationic | Natural | Derived from Callyspongia aerizusa | Mycobacterium Tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 10 μg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 26213786 |
| antitb_1638 | Callyaerins 7 | I-(Hyp)-VILPPLPIFG | Free | Amidation | Hyp= Hydroxiproline, Residue 1-8 involved in cyclic bond formation | Cyclic | 11 | D | Cationic | Natural | Derived from Callyspongia aerizusa | NA | NA | IC50= 5 μg/ml | in vitro | THP-1 cell line | 50% reduction in bacterial load | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 26213786 |
| antitb_1639 | Callyaerins 7 | I-(Hyp)-VILPPLPIFG | Free | Amidation | Hyp= Hydroxiproline, Residue 1-8 involved in cyclic bond formation | Cyclic | 11 | D | Cationic | Natural | Derived from Callyspongia aerizusa | NA | NA | IC90 = 30μg/ml | in vitro | THP-1 cell line | 90% reduction in bacterial load | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 26213786 |